NL-OMON36391已完成2 期
A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with COPD. - MAB115032
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •COPD patients >=40 years of age.
- •(Ex) smokers, at least 10 pack years.
- •Post salbutamol FEV1/FVC ratio <70%.
- •Post salbutamol FEV1 30-70% of predicted.
- •Safe contraception for women of childbearing potential.
排除标准
- •Pregnancy.
- •Bronchial asthma.
- •Oral steroids in the past 6 weeks.
- •Hospitalization in the past 12 weeks for COPD or pneumonia.
- •Antibiotics for lower respiratory tract infection in the past 6 weeks.
- •BMI >35 kg/m2.
- •Pacemaker.
- •Significant ECG abnormalities (see protocol for details).
- •Contraindications for the use of anticholinergics.
- •Treatment with specified (mainly COPD) therapies within a specified time frame (see protocol for details).
研究者
相似试验
进行中（未招募）
不适用
A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with COPD.Chronic Obstructive Pulmonary DiseaseEUCTR2010-022796-62-SEGlaxoSmithKline Research & Development Ltd425
进行中（未招募）
不适用
A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with COPD.Chronic Obstructive Pulmonary DiseaseEUCTR2010-022796-62-SKGlaxoSmithKline Research & Development Ltd425
进行中（未招募）
不适用
A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with COPD.Chronic Obstructive Pulmonary DiseaseEUCTR2010-022796-62-NLGlaxoSmithKline Research & Development Ltd425
进行中（未招募）
不适用
A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with COPD.Chronic Obstructive Pulmonary Disease.EUCTR2010-022796-62-EEGlaxoSmithKline Research & Development Ltd425
进行中（未招募）
不适用
A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with COPD.Chronic Obstructive Pulmonary DiseaseEUCTR2010-022796-62-DEGlaxoSmithKline Research & Development Ltd425